Phuturdex › Drugs › Pirfenidone
Drugs in development · updated 30 October 2026
Pirfenidone: clinical trials and development status
Other names and codes: Esbriet
As of 30 October 2026 Pirfenidone is in 20 active clinical trials (recruiting or ongoing, phases I–III) for 20 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pirfenidone and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Idiopathic pulmonary fibrosis | III | 6 | NCT07284602 |
| Pulmonary fibrosis | III | 3 | NCT07284602 |
| Acute respiratory distress syndrome | III | 1 | NCT05075161 |
| COVID-19 | III | 1 | NCT06928272 |
| Lung disease | III | 1 | NCT07284602 |
| Pneumoconiosis | III | 1 | NCT05288179 |
| Post-Acute COVID-19 Syndrome | III | 1 | NCT06928272 |
| Breast neoplasm | II | 2 | NCT05704166 |
| Colorectal neoplasm | II | 2 | NCT07644286 |
| Pancreatitis | II | 2 | NCT07755813 |
| Acute lung injury | II | 1 | NCT05704166 |
| Chronic pancreatitis | II | 1 | NCT07755813 |
| Chronic progressive multiple sclerosis | I–II | 1 | NCT03109288 |
| Metastasis | II | 1 | NCT07856914 |
| Multiple sclerosis | I–II | 1 | NCT03109288 |
| Neoplasm | II | 1 | NCT07856914 |
| Peritoneal neoplasm | II | 1 | NCT07856914 |
| Respiration disorder | II | 1 | NCT05321420 |
| Triple-negative breast neoplasm | I–II | 1 | NCT07161791 |
| Idiopathic tracheal stenosis | I | 1 | NCT07654517 |
Everything on Pirfenidone
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.